Back to search

Switzerland· 68609001

Opdualag (80 mg Relatlimab / 240 mg Nivolumab pro 20 ml), Konzentrat zur Herstellung einer Infusionslösung

A nivolumab and relatlimab product containing relatlimabum, nivolumabum, registered in Switzerland by Bristol-Myers Squibb SA and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC L01FY02

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedOpdualag (80 mg Relatlimab / 240 mg N…ATCL01FY02REGISTER NO.68609001PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Nivolumab and relatlimab is registered in 13 of 19 countries.

Countries holding a registration under ATC L01FY02 (nivolumab and relatlimab), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 9 of them publish a price we can compare per daily dose

Nivolumab and relatlimab · ATC L01FY02

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Swissmedic (Switzerland)
Active substance
relatlimabum, nivolumabum
Manufacturer
Bristol-Myers Squibb SA
Country
Switzerland (CH)
ATC code
L01FY02
ATC class
Nivolumab and relatlimab
Swissmedic category
A
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680686090019
    Durchstf 20 ml
    CHF 5960.15

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f8be2901-24aa-46b4-9f0f-606178c9419c
GET /v1/drugs/f8be2901-24aa-46b4-9f0f-606178c9419c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "relatlimabum 80 mg + nivolumabum 240 mg",
  "valid_from": "2024-02-01",
  "limitations": "[{\"description\":\"OPDUALAG ist für die Erstlinienbehandlung von Erwachsenen mit nicht resezierbarem oder metastasiertem Melanom mit einer PD-L1-Expression < 1% indiziert.<br>\\nBristol Myers Squibb erstattet dem Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, für jede bezogene Packung einen festgelegten Anteil des Fabrikabgabepreises zurück. Sie gibt dem Krankenversicherer die Höhe der Rückerstattung bekannt. Die Mehrwertsteuer kann nicht zusätzlich zu diesem Anteil des Fabrikabgabepreises zurückgefordert werden. Die Aufforderung zur Rückerstattung soll ab dem Zeitpunkt der Verabreichung erfolgen.<br>\\nFolgender Code ist an den Krankenversicherer zu übermitteln: 21515.01<br>\\n<br>\",\"costApproval\":null,\"indication\":\"21515.01\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-01-01\",\"validTo\":\"2027-01-31\"}]",
  "galenic_form": "Inf Konz",
  "therapeutic_area": null,
  "sl_inclusion_date": "2024-02-01",
  "self_retention_pct": 10
}

See everything about nivolumab and relatlimab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.